metlit.ai

What It Is

METLiT is an AI-native molecular diagnostics system for magnetic resonance spectroscopy (MRS). Its goal is to turn metabolic information that standard MRI scanners already capture—but that remains underused in clinical practice—into actionable results. It is not a general-purpose imaging AI tool, but a fully automated workflow for MRS, from raw data to clinical reporting.

Core Capabilities

The system uses an “AI Agentic Architecture,” where multiple specialized agents collaborate on preprocessing, quality assessment, metabolite quantification, clinical interpretation, and report generation. Technically, it emphasizes MRS physics-based modeling rather than a purely black-box approach. It also uses Bayesian deep learning for uncertainty quantification, attaching confidence levels to results. Its core engine claims to quantify more than 17 metabolites, including Glu, Gln, GABA, and GSH, and supports mainstream MRI platforms from GE, Philips, and Siemens without requiring special sequences.

Pricing and Trial

The website does not disclose pricing, licensing models, per-case billing, or subscription plans, nor does it state whether a free trial is available. The main entry points are demo requests, research collaborations, and IR material requests, suggesting that commercialization is still primarily geared toward institution-level discussions.

Pros and Cons

Its main strength is that it targets key barriers to clinical adoption of MRS: heavy reliance on experts, complex workflows, inconsistent vendor formats, and difficulty standardizing reports. It also provides relatively rich information on papers, patents, and multi-center collaborations, giving it more technical credibility than typical marketing-driven AI tools. The limitations are also clear: it does not disclose details on data privacy, cloud vs. on-prem deployment, interface standards, regulatory approvals, or real-world clinical performance metrics. The website also indicates plans to pursue medical device regulatory submissions and global commercial deployment after 2026, so its actual clinical readiness still needs further verification.

Who It’s For

METLiT is better suited to imaging departments at large hospitals, neurology departments, precision medicine centers, pharmaceutical clinical trial teams, and universities or medical institutions conducting MRS research. It is not intended for ordinary individual users or general AI tool users.

Access in China and Alternatives

The website does not provide information on access from China, and payment methods are not disclosed. For use in domestic medical institutions, users would still need to confirm network connectivity, cross-border data transfer requirements, medical device registration, and local support capabilities. Comparable alternatives include LCModel, Tarquin, Osprey, jMRUI, and MRS analysis tools bundled by MRI vendors. For clinical-grade deployment, domestic imaging AI platforms and hospital-built research workflows should also be considered.